Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma

被引:32
作者
Halperin, R [1 ]
Zehavi, S
Hadas, E
Habler, L
Bukovsky, I
Schneider, D
机构
[1] Assaf Harofe Med Ctr, Dept Obstet & Gynecol, IL-70300 Zerifin, Israel
[2] Assaf Harofe Med Ctr, Dept Pathol, IL-70300 Zerifin, Israel
[3] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[4] Sci Based Ind Pk, Ness Ziona, Israel
关键词
primary peritoneal serous papillary carcinoma; ovarian serous papillary cancer; immunohistochemistry; estrogen and progesterone receptors; Ki-67; HER-2/neu; p53;
D O I
10.1097/00004347-200110000-00005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Twenty-six patients, meeting strict criteria for primary peritoneal serous papillary carcinoma (PPSPC), were matched to 22 patients with ovarian serous papillary cancer (OSPC) for age and stage. Immunohistochemistry was used to determine the status of estrogen receptors (ER), progesterone receptors (PR), the expression of cell proliferation marker Ki-67, and the overexpression of HER-2/neu and p53 protein. Of the PPSPCs, 53.8% were poorly differentiated, as were 18.2% of the OSPCs (p=0.012). Positive immunostaining for ER and PR was less in PPSPCs (30.8% and 46.2%, respectively) than OSPCs (72.7% and 90.9%; p=0.003 and p=0.001, respectively). Conversely, a significant increase in the expression of Ki-67 was found in PPSPCs (37.7%) versus OSPCs (26.8%) (p=0.039). The same trend was found for HER-2/neu, being overexpressed in 38.5% of the PPSPC versus 9.1% of the OSPCs (p=0.019). Overexpression of p53 was found in 30.8% of the PPSPCs and 45.4% of the OSPCs (not significant). There was a significantly worse survival rate for PPSPCs than for OSPCs (p=0.017), yet none of the studied parameters were significantly correlated with survival within the PPSPC and OSPC groups., The significantly different immunohistochemical expression of ER, PR, Ki-67, and HER-2 in PPSPCs compared with OSPCs suggests that different molecular events may lead to tumorigenesis in these two cancers.
引用
收藏
页码:341 / 345
页数:5
相关论文
共 27 条
[1]   PRIMARY PERITONEAL PAPILLARY SEROUS ADENOCARCINOMA - CLINICAL AND MANAGEMENT ASPECTS [J].
ALTARAS, MM ;
AVIRAM, R ;
COHEN, I ;
CORDOBA, M ;
WEISS, E ;
BEYTH, Y .
GYNECOLOGIC ONCOLOGY, 1991, 40 (03) :230-236
[2]  
ARTEAGA CL, 1994, CANCER RES, V54, P3758
[3]  
BIZZI A, 1988, CANCER RES, V48, P6222
[4]   EXTRAOVARIAN PERITONEAL SEROUS PAPILLARY CARCINOMA - A CASE-CONTROL RETROSPECTIVE COMPARISON TO PAPILLARY ADENOCARCINOMA OF THE OVARY [J].
BLOSS, JD ;
LIAO, SY ;
BULLER, RE ;
MANETTA, A ;
BERMAN, ML ;
MCMEEKIN, S ;
BLOSS, LP ;
DISAIA, PJ .
GYNECOLOGIC ONCOLOGY, 1993, 50 (03) :347-351
[5]  
BOOKMAN M, 1996, PROTOCOL GOG, V160
[6]  
*CANC COMM INT FED, 1986, GYNECOL ONCOL, V25, P383
[7]  
ELTABBAKH G, 1996, GYNECOL ONCOL, V60, P146
[8]  
FROMM GL, 1990, OBSTET GYNECOL, V75, P89
[9]   Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary [J].
Geisler, JP ;
Wiemann, MC ;
Miller, GA ;
Geisler, HE .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :424-427
[10]  
GOONERATNE S, 1981, INT J GYNECOL PATHOL, V1, P241